deltatrials
Completed PHASE3 INTERVENTIONAL 2-arm NCT03783442

A Study of Tislelizumab (BGB-A317) in Combination With Chemotherapy as First Line Treatment in Participants With Advanced Esophageal Squamous Cell Carcinoma

A Randomized, Placebo-Controlled, Double-Blind Phase 3 Study to Evaluate the Efficacy and Safety of Tislelizumab (BGB-A317) in Combination With Chemotherapy as First-Line Treatment in Patients With Unresectable, Locally Advanced Recurrent or Metastatic Esophageal Squamous Cell Carcinoma

Sponsor: BeiGene

Conditions Esophageal Squamous Cell Carcinoma (ESCC)
Interventions Capecitabine Cisplatin Fluorouracil (5-FU) Oxaliplatin Paclitaxel Placebo Tislelizumab
Updated 26 times since 2019 Last updated: Jul 28, 2025 Started: Dec 11, 2018 Primary completion: Feb 28, 2022 Completion: Aug 22, 2024
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE3 clinical study on Esophageal Squamous Cell Carcinoma (ESCC), this trial is completed. The trial is conducted by BeiGene and has accumulated 26 data snapshots since 2018. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

~Jan 2019 – ~Mar 2019 · 59 days · monthly snapshot~Mar 2019 – ~Apr 2019 · 31 days · monthly snapshot~Apr 2019 – ~Jun 2019 · 2 months · monthly snapshot~Jun 2019 – ~Jul 2019 · 30 days · monthly snapshot~Jul 2019 – ~Aug 2019 · 31 days · monthly snapshot~Aug 2019 – ~Sep 2019 · 31 days · monthly snapshot~Sep 2019 – ~Oct 2019 · 30 days · monthly snapshot~Oct 2019 – ~Nov 2019 · 31 days · monthly snapshot~Nov 2019 – ~Dec 2019 · 30 days · monthly snapshot~Dec 2019 – ~Jan 2020 · 31 days · monthly snapshot~Jan 2020 – ~Mar 2020 · 2 months · monthly snapshot~Mar 2020 – ~Jun 2020 · 3 months · monthly snapshot~Jun 2020 – ~Oct 2020 · 4 months · monthly snapshot~Oct 2020 – ~Jan 2021 · 3 months · monthly snapshot~Jan 2021 – ~Feb 2021 · 31 days · monthly snapshot~Feb 2021 – ~May 2022 · 15 months · monthly snapshot~May 2022 – ~Jun 2022 · 31 days · monthly snapshot~Jun 2022 – ~May 2023 · 11 months · monthly snapshot~May 2023 – ~Dec 2023 · 7 months · monthly snapshot~Dec 2023 – ~May 2024 · 5 months · monthly snapshot~May 2024 – ~Jul 2024 · 2 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Nov 2024 · 2 months · monthly snapshot~Nov 2024 – ~Aug 2025 · 9 months · monthly snapshot~Aug 2025 – ~Sep 2025 · 31 days · monthly snapshot~Sep 2025 – present · 10 months · monthly snapshot

Change History

26 versions recorded

  1. Sep 2025 — Present [monthly]

    Completed PHASE3

  2. Aug 2025 — Sep 2025 [monthly]

    Completed PHASE3

  3. Nov 2024 — Aug 2025 [monthly]

    Completed PHASE3

    Status: Active Not Recruiting → Completed

  4. Sep 2024 — Nov 2024 [monthly]

    Active Not Recruiting PHASE3

  5. Jul 2024 — Sep 2024 [monthly]

    Active Not Recruiting PHASE3

▶ Show 21 earlier versions

  1. May 2024 — Jul 2024 [monthly]

    Active Not Recruiting PHASE3

  2. Dec 2023 — May 2024 [monthly]

    Active Not Recruiting PHASE3

  3. May 2023 — Dec 2023 [monthly]

    Active Not Recruiting PHASE3

  4. Jun 2022 — May 2023 [monthly]

    Active Not Recruiting PHASE3

  5. May 2022 — Jun 2022 [monthly]

    Active Not Recruiting PHASE3

  6. Feb 2021 — May 2022 [monthly]

    Active Not Recruiting PHASE3

    Status: Recruiting → Active Not Recruiting

  7. Jan 2021 — Feb 2021 [monthly]

    Recruiting PHASE3

  8. Oct 2020 — Jan 2021 [monthly]

    Recruiting PHASE3

  9. Jun 2020 — Oct 2020 [monthly]

    Recruiting PHASE3

  10. Mar 2020 — Jun 2020 [monthly]

    Recruiting PHASE3

  11. Jan 2020 — Mar 2020 [monthly]

    Recruiting PHASE3

  12. Dec 2019 — Jan 2020 [monthly]

    Recruiting PHASE3

  13. Nov 2019 — Dec 2019 [monthly]

    Recruiting PHASE3

  14. Oct 2019 — Nov 2019 [monthly]

    Recruiting PHASE3

  15. Sep 2019 — Oct 2019 [monthly]

    Recruiting PHASE3

  16. Aug 2019 — Sep 2019 [monthly]

    Recruiting PHASE3

  17. Jul 2019 — Aug 2019 [monthly]

    Recruiting PHASE3

  18. Jun 2019 — Jul 2019 [monthly]

    Recruiting PHASE3

  19. Apr 2019 — Jun 2019 [monthly]

    Recruiting PHASE3

  20. Mar 2019 — Apr 2019 [monthly]

    Recruiting PHASE3

  21. Jan 2019 — Mar 2019 [monthly]

    Recruiting PHASE3

    First recorded

Dec 2018

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • BeiGene
Data source: BeiGene

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

AkashiShi, Japan , Akitashi, Japan , Amagasakishi, Japan , Anderlecht, Belgium , Arkhangelsk, Russia , Barcelona, Spain , Beijing, China , Brest, France , Bruges, Belgium , Brzozów, Poland and 94 more locations